BACKGROUND: The tyrosine kinase inhibitor imatinib mesylate was developed as an inhibitor of the kinase activity of BCR-ABL. However, imatinib also has potent inhibitory activity against the platelet-derived growth factor receptor (PDGFR). Nilotinib is approved for treating patients with chronic myeloid leukemia showing resistance or intolerance to imatinib. Like imatinib, nilotinib selectively inhibits the tyrosine kinase activity of PDGFR. OBJECTIVES: We examined the effect of imatinib and nilotinib on acute lung injury and pulmonary fibrosis in a mouse model. METHODS: Mice were treated by intratracheal instillation of bleomycin. Imatinib or nilotinib were administered by oral gavage. To study the early inflammatory and late fibrotic phases of lung injury, mice were sacrificed on days 3, 7, 14 and 21 after bleomycin instillation. RESULTS: Histopathology showed that imatinib and nilotinib attenuated the extent of lung injury and fibrosis. The numbers of inflammatory cells and levels of IL-6, IL-1β and tumor necrosis factor-α were decreased in the imatinib and nilotinib groups on days 3 and 7. Imatinib and nilotinib therapy significantly reduced the levels of hydroxyproline on days 14 and 21, which was accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFR-β. Imatinib and nilotinib also significantly reduced the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Imatinib and nilotinib treatment also significantly inhibited the PDGF-induced proliferation of lung fibroblasts in vitro. When imatinib or nilotinib was given 7 days after the instillation of bleomycin, only nilotinib attenuated pulmonary fibrosis. CONCLUSIONS: Imatinib and nilotinib attenuated bleomycin-induced acute lung injury and pulmonary fibrosis in mice. In a therapeutic model, nilotinib showed more potent antifibrotic effects than imatinib.
BACKGROUND: The tyrosine kinase inhibitor imatinib mesylate was developed as an inhibitor of the kinase activity of BCR-ABL. However, imatinib also has potent inhibitory activity against the platelet-derived growth factor receptor (PDGFR). Nilotinib is approved for treating patients with chronic myeloid leukemia showing resistance or intolerance to imatinib. Like imatinib, nilotinib selectively inhibits the tyrosine kinase activity of PDGFR. OBJECTIVES: We examined the effect of imatinib and nilotinib on acute lung injury and pulmonary fibrosis in a mouse model. METHODS: Mice were treated by intratracheal instillation of bleomycin. Imatinib or nilotinib were administered by oral gavage. To study the early inflammatory and late fibrotic phases of lung injury, mice were sacrificed on days 3, 7, 14 and 21 after bleomycin instillation. RESULTS: Histopathology showed that imatinib and nilotinib attenuated the extent of lung injury and fibrosis. The numbers of inflammatory cells and levels of IL-6, IL-1β and tumor necrosis factor-α were decreased in the imatinib and nilotinib groups on days 3 and 7. Imatinib and nilotinib therapy significantly reduced the levels of hydroxyproline on days 14 and 21, which was accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFR-β. Imatinib and nilotinib also significantly reduced the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Imatinib and nilotinib treatment also significantly inhibited the PDGF-induced proliferation of lung fibroblasts in vitro. When imatinib or nilotinib was given 7 days after the instillation of bleomycin, only nilotinib attenuated pulmonary fibrosis. CONCLUSIONS: Imatinib and nilotinib attenuated bleomycin-induced acute lung injury and pulmonary fibrosis in mice. In a therapeutic model, nilotinib showed more potent antifibrotic effects than imatinib.
Authors: Roy G Brower; Michael A Matthay; Alan Morris; David Schoenfeld; B Taylor Thompson; Arthur Wheeler Journal: N Engl J Med Date: 2000-05-04 Impact factor: 91.245
Authors: M I Hertz; C A Henke; R E Nakhleh; K R Harmon; W A Marinelli; J M Fox; S H Kubo; S J Shumway; R M Bolman; P B Bitterman Journal: Proc Natl Acad Sci U S A Date: 1992-11-01 Impact factor: 11.205
Authors: P W Manley; S W Cowan-Jacob; E Buchdunger; D Fabbro; G Fendrich; P Furet; T Meyer; J Zimmermann Journal: Eur J Cancer Date: 2002-09 Impact factor: 9.162
Authors: Ruairi J Fahy; Frank Lichtenberger; Christine B McKeegan; Gerard J Nuovo; Clay B Marsh; Mark D Wewers Journal: Am J Respir Cell Mol Biol Date: 2003-04 Impact factor: 6.914
Authors: Alfiya Akhmetshina; Clara Dees; Margarita Pileckyte; Britta Maurer; Roland Axmann; Astrid Jüngel; Jochen Zwerina; Steffen Gay; Georg Schett; Oliver Distler; Jörg H W Distler Journal: FASEB J Date: 2008-03-07 Impact factor: 5.191
Authors: Alicia N Rizzo; Jurjan Aman; Geerten P van Nieuw Amerongen; Steven M Dudek Journal: Arterioscler Thromb Vasc Biol Date: 2015-03-26 Impact factor: 8.311
Authors: E Letsiou; A N Rizzo; S Sammani; P Naureckas; J R Jacobson; J G N Garcia; S M Dudek Journal: Am J Physiol Lung Cell Mol Physiol Date: 2014-12-05 Impact factor: 5.464
Authors: Andrew Rasky; David M Habiel; Susan Morris; Matthew Schaller; Bethany B Moore; Sem Phan; Steven L Kunkel; Martin Phillips; Cory Hogaboam; Nicholas W Lukacs Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-11-20 Impact factor: 5.464
Authors: Carmel B Nanthakumar; Richard J D Hatley; Seble Lemma; Jack Gauldie; Richard P Marshall; Simon J F Macdonald Journal: Nat Rev Drug Discov Date: 2015-09-04 Impact factor: 84.694